stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. RNXT
    stockgist
    HomeTop MoversCompaniesConcepts
    RNXT logo

    RenovoRx, Inc.

    RNXT
    NASDAQ
    Healthcare
    Biotechnology
    Mountain View, CA, US10 employeesrenovorx.com
    $1.02
    +0.05(5.15%)

    52W $0.73 – $1.42

    AI-generated

    RenovoRx delivered strong revenue growth in FY2025 from increased adoption and repeat use of RenovoCath, but expanded operating losses reflect continued investment in commercial infrastructure amid ongoing clinical development.

    Revenue breakdown: All Other Segments (100%).

    $37MMkt Cap
    $928.1KRev TTM
    -$11MNI TTM
    -3.7xP/E TTM

    Latest Earnings

    10-K
    FY FY2025Mar 29, 2026

    RenovoRx delivered strong revenue growth in FY2025 from increased adoption and repeat use of RenovoCath, but expanded operating losses reflect continued investment in commercial infrastructure amid ongoing clinical development.

    Read full analysisView SEC Filing

    What Changed Recently

    Management Change
    Mar 26, 2026

    . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On March 24,

    Management Change
    Feb 5, 2026

    . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On February

    Financial Results
    Mar 29, 2026

    | Results of Operations and Financial Condition. | |---|---| On March 30, 2026, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial r

    Material Agreement+3 More
    Mar 22, 2026

    . Entry into a Material Definitive Agreement. On March 17, 2026, RenovoRx, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agre

    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    All Other Segments100%($1M)
    Analyst View

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    MAIAMAIA Biotechnology, Inc.$1.34-0.37%$52M—
    ELUTElutia Inc.$1.18+8.26%$50M0.9
    ANVSAnnovis Bio, Inc.$2.27+7.31%$45M-2.1
    PYPDPolyPid Ltd.$4.38-0.34%$45M-2.5
    CELUCelularity Inc.$1.34+2.29%$32M-0.4
    TVRDTvardi Therapeutics, Inc.$3.03+1.00%$28M-2.4
    LTRNLantern Pharma Inc.$1.59+12.32%$18M-1.3
    CALCCalciMedica, Inc.$0.58-1.94%$9M-328.3
    Company Profile
    CIK0001574094
    ISINUS75989R1077
    CUSIP75989R107
    Phone650 284 4433
    Address4546 El Camino Real, Mountain View, CA, 94022, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice